Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

Nat Med. 2014 Oct;20(10):1126-9. doi: 10.1038/nm.3702. Epub 2014 Sep 7.

Abstract

Ebolavirus disease causes high mortality, and the current outbreak has spread unabated through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus glycoprotein (GP) generate protective immunity against acute lethal Zaire ebolavirus (EBOV) challenge in macaques, but fail to protect animals immune to Ad5, suggesting natural Ad5 exposure may limit vaccine efficacy in humans. Here we show that a chimpanzee-derived replication-defective adenovirus (ChAd) vaccine also rapidly induced uniform protection against acute lethal EBOV challenge in macaques. Because protection waned over several months, we boosted ChAd3 with modified vaccinia Ankara (MVA) and generated, for the first time, durable protection against lethal EBOV challenge.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Adenovirus Vaccines / administration & dosage
  • Adenovirus Vaccines / genetics
  • Adenovirus Vaccines / immunology
  • Adenoviruses, Human / genetics
  • Adenoviruses, Human / immunology
  • Adenoviruses, Simian / genetics
  • Adenoviruses, Simian / immunology
  • Animals
  • Defective Viruses / genetics
  • Defective Viruses / immunology
  • Ebola Vaccines / administration & dosage
  • Ebola Vaccines / genetics
  • Ebola Vaccines / immunology*
  • Ebolavirus / genetics
  • Ebolavirus / immunology*
  • Female
  • Genetic Vectors
  • Hemorrhagic Fever, Ebola / immunology*
  • Hemorrhagic Fever, Ebola / prevention & control*
  • Hemorrhagic Fever, Ebola / virology
  • Humans
  • Immunization, Secondary
  • Macaca fascicularis
  • Pan troglodytes
  • RNA, Viral / blood
  • RNA, Viral / genetics
  • Time Factors
  • Vaccinia virus / genetics
  • Vaccinia virus / immunology

Substances

  • Adenovirus Vaccines
  • Ebola Vaccines
  • RNA, Viral